Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2024.
Financials
Financial year 2025
PHARMACIE MERTENS from Celles (lez-Tournai), company number BE0442845481, closed financial year 2025 with a result of € 148,976 after tax. For that financial year PHARMACIE MERTENS recorded a gross margin of € 319,439 and equity of € 490,595. Compared with financial year 2024, the result moved from € 205,285 to € 148,976. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 13, 2026.
€ 490,595
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 148,976
▼ 27% vs 2024
Profit after tax over the fiscal year.
€ 87,122
▼ 14% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 130,000 paid out
87 % of the profit went to the shareholders, mostly to ESCAPHARM (99 % of the shares). That is where the money ends up.
People and assets in 2025
1.5
▲ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 67,142
▲ 37% vs 2024
€ 44,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 51,789
▲ 48% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 736,589
▼ 7% vs 2024
€ 68,963 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 299,560
▲ 18% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,750
▲ 51% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 315,907 | € 312,135 | € 351,128 | € 319,439 | ▼ 9% |
| Profit after taxes | € 178,194 | € 164,402 | € 205,285 | € 148,976 | ▼ 27% |
| Equity | € 431,932 | € 446,334 | € 471,619 | € 490,595 | ▲ 4% |
| Total debts | € 1,128,287 | € 1,150,549 | € 1,233,770 | € 1,182,899 | ▼ 4% |
| Cash | € 204,930 | € 130,512 | € 101,896 | € 87,122 | ▼ 14% |
| Land & buildings | € 570,897 | € 645,437 | € 608,984 | € 258,413 | ▼ 58% |
| Retained profit | € 413,332 | € 427,734 | € 453,019 | € 471,995 | ▲ 4% |
| Dividend | € 150,000 | € 150,000 | € 180,000 | € 130,000 | ▼ 28% |
| Bank debt | € 850,732 | € 833,041 | € 789,623 | € 736,589 | ▼ 7% |
| Balance sheet total | € 1,560,219 | € 1,596,884 | € 1,705,389 | € 1,673,494 | ▼ 2% |
| Employees (FTE) | 1.3 | 1.2 | 1.2 | 1.5 | ▲ 0.3 |
Key figures of PHARMACIE MERTENS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIE MERTENS?
What happened at PHARMACIE MERTENS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 148,976 (▼ 27% vs 2024). filed late Source: NBB ↗
- New establishment in Celles (lez-Tournai). KBO
- Start of the company according to the CBE. KBO
In short
From € 178,194 profit in 2022 to € 148,976 profit in 2025.
Paid € 31,964 in corporate taxes since 2022.
Best year ever: 2024, with € 205,285 profit.
On average € 213,000 of value added per employee in 2025.
A new publication or filing at PHARMACIE MERTENS? We notify you, reason included.
Follow PHARMACIE MERTENSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of ESCAPHARM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMACIE MERTENSBehind PHARMACIE MERTENS is ESCAPHARM BV. The shares are held by ESCAPHARM (99.2%).
Directors
According to the 2025 annual accounts
Director · represented by Renaud Mertens
Shareholders
99.2%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Monseigneur Descamps 18
7760 Celles (lez-Tournai)
Place d'Escanaffles 134
7760 Celles (lez-Tournai)
Active since 4 March 1991
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0442.845.481
- VAT number
- BE 0442.845.481
- Registered office
- Rue Monseigneur Descamps 18, 7760 Celles (lez-Tournai)
- Names & denominations
- PHARMACIE MERTENS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 1990
- Peppol
- Active · Active since 4 Sept 2025
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten